June 22, 2022
The U.S. FDA has approved an expanded indication for Vaxneuvance™ (pneumococcal 15valent conjugate vaccine) to include pediatric patients.
- First FDA approved in 2021 to vaccinate adults, Vaxneuvance is now indicated to provide active immunization in patients at least six weeks of age to prevent invasive disease caused by fifteen specific variants of Streptococcus pneumoniae.
- Vaxneuvance is administered via intramuscular injection. The recommended dosing is:
- Ages six weeks through 17 years: A series of four 0.5mL doses given at 2, 4, 6, and 12 through 15 months of age.
- Ages 18 and up: A single 0.5mL dose.